Table of Content

1. Executive Summary
   1. Global Pulmonary Fibrosis Treatment Market Snapshot, 2025 and 2032
   2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
   3. Key Market Trends
   4. Future Market Projections
   5. Premium Market Insights
   6. Industry Developments and Key Market Events
   7. PMR Analysis and Recommendations
2. Market Overview
   1. Market Scope and Definition
   2. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunity
      4. Challenges
      5. Key Trends
   3. Macro-Economic Factors
      1. Global Sectorial Outlook
      2. Global GDP Growth Outlook
   4. COVID-19 Impact Analysis
   5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   1. Regulatory Landscape
   2. Product Adoption Analysis
   3. Value Chain Analysis
   4. Key Deals and Mergers
   5. PESTLE Analysis
   6. Porter’s Five Force Analysis
4. Global Pulmonary Fibrosis Treatment Market Outlook:
   1. Key Highlights
      1. Market Size (US$ Mn) and Y-o-Y Growth
      2. Absolute $ Opportunity
   2. Market Size (US$ Mn) Analysis and Forecast
      1. Historical Market Size (US$ Mn) Analysis, 2019-2024
      2. Market Size (US$ Mn) Analysis and Forecast, 2025-2032
   3. Global Pulmonary Fibrosis Treatment Market Outlook: Drug
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Mn) Analysis, By Drug, 2019 - 2024
      3. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
         1. Pirfenidone
         2. Nintedanib
         3. Others
      4. Market Attractiveness Analysis: Drug
   4. Global Pulmonary Fibrosis Treatment Market Outlook: Route of Administration
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019 - 2024
      3. Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025 - 2032
         1. Oral
         2. Injectable
      4. Market Attractiveness Analysis: Route of Administration
   5. Global Pulmonary Fibrosis Treatment Market Outlook: Indication
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019 - 2024
      3. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
         1. Idiopathic Pulmonary Fibrosis (IPF)
         2. Progressive Pulmonary Fibrosis (PPF)
         3. Others
      4. Market Attractiveness Analysis: Indication
   6. Global Pulmonary Fibrosis Treatment Market Outlook: Distribution Channel
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019 - 2024
      3. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
         1. Hospital Pharmacies
         2. Retail Pharmacies
         3. Online Pharmacies
      4. Market Attractiveness Analysis: Distribution Channel
5. Global Pulmonary Fibrosis Treatment Market Outlook: Region
   1. Key Highlights
   2. Historical Market Size (US$ Mn) Analysis, By Region, 2019 - 2024
   3. Market Size (US$ Mn) Analysis and Forecast, By Region, 2025 - 2032
      1. North America
      2. Europe
      3. East Asia
      4. South Asia and Oceania
      5. Latin America
      6. Middle East & Africa
   4. Market Attractiveness Analysis: Region
6. North America Pulmonary Fibrosis Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug
      3. By Route of Administration
      4. By Indication
      5. By Distribution Channel
   3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
      1. U.S.
      2. Canada
   4. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
      1. Pirfenidone
      2. Nintedanib
      3. Others
   5. Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injectable
   6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Idiopathic Pulmonary Fibrosis (IPF)
      2. Progressive Pulmonary Fibrosis (PPF)
      3. Others
   7. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   8. Market Attractiveness Analysis
7. Europe Pulmonary Fibrosis Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug
      3. By Route of Administration
      4. By Indication
      5. By Distribution Channel
   3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
      6. Russia
      7. Rest of Europe
   4. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
      1. Pirfenidone
      2. Nintedanib
      3. Others
   5. Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injectable
   6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Idiopathic Pulmonary Fibrosis (IPF)
      2. Progressive Pulmonary Fibrosis (PPF)
      3. Others
   7. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   8. Market Attractiveness Analysis
8. East Asia Pulmonary Fibrosis Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug
      3. By Route of Administration
      4. By Indication
      5. By Distribution Channel
   3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
      1. China
      2. Japan
      3. South Korea
   4. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
      1. Pirfenidone
      2. Nintedanib
      3. Others
   5. Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injectable
   6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Idiopathic Pulmonary Fibrosis (IPF)
      2. Progressive Pulmonary Fibrosis (PPF)
      3. Others
   7. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   8. Market Attractiveness Analysis
9. South Asia & Oceania Pulmonary Fibrosis Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug
      3. By Route of Administration
      4. By Indication
      5. By Distribution Channel
   3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
      1. India
      2. Southeast Asia
      3. ANZ
      4. Rest of South Asia & Oceania
   4. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
      1. Pirfenidone
      2. Nintedanib
      3. Others
   5. Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injectable
   6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Idiopathic Pulmonary Fibrosis (IPF)
      2. Progressive Pulmonary Fibrosis (PPF)
      3. Others
   7. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   8. Market Attractiveness Analysis
10. Latin America Pulmonary Fibrosis Treatment Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Drug
       3. By Route of Administration
       4. By Indication
       5. By Distribution Channel
    3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
       1. Brazil
       2. Mexico
       3. Rest of Latin America
    4. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
       1. Pirfenidone
       2. Nintedanib
       3. Others
    5. Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025 - 2032
       1. Oral
       2. Injectable
    6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
       1. Idiopathic Pulmonary Fibrosis (IPF)
       2. Progressive Pulmonary Fibrosis (PPF)
       3. Others
    7. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    8. Market Attractiveness Analysis
11. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Drug
       3. By Route of Administration
       4. By Indication
       5. By Distribution Channel
    3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
       1. GCC Countries
       2. Egypt
       3. South Africa
       4. Northern Africa
       5. Rest of Middle East & Africa
    4. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
       1. Pirfenidone
       2. Nintedanib
       3. Others
    5. Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025 - 2032
       1. Oral
       2. Injectable
    6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
       1. Idiopathic Pulmonary Fibrosis (IPF)
       2. Progressive Pulmonary Fibrosis (PPF)
       3. Others
    7. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    8. Market Attractiveness Analysis
12. Competition Landscape
    1. Market Share Analysis, 2024
    2. Market Structure
       1. Competition Intensity Mapping By Market
       2. Competition Dashboard
    3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       1. F. Hoffman - La Roche Ltd.
          1. Overview
          2. Segments and Products
          3. Key Financials
          4. Market Developments
          5. Market Strategy
       2. Boehringer Ingelheim
       3. International GmbH
       4. Cipla Ltd
       5. MediciNova, Inc.
       6. Intas Pharmaceuticals Ltd.
       7. Others
13. Appendix
    1. Research Methodology
    2. Research Assumptions
    3. Acronyms and Abbreviations